Cooper Stock Price, News & Analysis

CooperSurgical announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of their Fetal Pillow device during cesarean sections when a baby's head becomes stuck in the pelvis. This guidance is expected to enhance clinical practice and improve patient outcomes, particularly by shortening hospital stays by an average of one day and reducing surgery time by 20 minutes. A significant 97% of U.S. physicians surveyed indicated they would recommend the Fetal Pillow to others. This endorsement is projected to increase the device's adoption in the UK alongside CooperSurgical's mission to enhance women's health.

CooperSurgical has announced that over 11,000 families have enrolled in its Newborn Possibilities Program, which offers free cord blood and tissue processing, along with five years of storage for families with qualifying medical needs. CBR, a brand under CooperSurgical, is recognized as the largest family newborn stem cell preservation company, emphasizing the potential life-changing benefits of cord blood and tissue for regenerative medicine. The enrollment program helps families with newborns who have specific health conditions, providing crucial access to stem cell therapy.

CooperCompanies (NYSE: COO) has announced its annual stockholders meeting scheduled for March 15, 2023. Stockholders on record as of the end of January 19, 2023, will be permitted to vote on matters outlined in the company's proxy statement, including the election of directors. The company, headquartered in San Ramon, CA, operates two main business units: CooperVision and CooperSurgical, focusing on vision care and women's health respectively.

CooperCompanies (NYSE: COO) has announced a semi-annual dividend of 3 cents per share, reflecting its commitment to return income to shareholders. This dividend is payable on February 10, 2023, to stockholders of record as of January 23, 2023. The decision aligns with the company’s board-approved plan for annual dividends, showcasing its financial stability and ongoing support for its investors.

CooperSurgical has partnered with Ostro to enhance consumer engagement for its hormone-free IUD, Paragard, which prevents pregnancy for up to 10 years. This collaboration aims to provide personalized experiences on Paragard.com, featuring live Nurse Navigators to assist potential users. The partnership focuses on educating consumers about Paragard, promoting its benefits, and ensuring easier access to healthcare providers. Holly Sheffield, President of CooperSurgical, emphasizes empowering women through this initiative, while Dr. Chase Feiger, CEO of Ostro, expresses honor in collaborating on this health initiative.

CooperCompanies (NYSE: COO) reported a 12% revenue increase in Q4 2022, totaling $848.1 million, and a 13% full-year revenue increase to $3.3 billion. However, GAAP diluted EPS fell 40% in Q4, reaching $1.32, and 87% for the full year, at $7.76. Non-GAAP diluted EPS also showed declines, evidencing challenges despite record annual revenue driven by market share gains in contact lenses and fertility. The Company provided a 2023 revenue guidance of $3.46-$3.52 billion, indicating organic growth of 6%-8%. The outlook excludes pending acquisitions.

CooperCompanies (NYSE: COO) will release its fourth quarter and full year 2022 financial results on December 8, 2022, at 4:15 PM ET. A conference call to discuss these results and corporate developments will follow at 5:00 PM ET. Investors can join the call via the live dial-in number 800-715-9871, using conference ID 2291153, or through a webcast on the company’s investor relations website. A recording of the call will be available post-event until December 15, 2022.

CooperVision has integrated SynergEyes into its Specialty EyeCare unit, enhancing its specialty contact lens offerings. This partnership aims to improve treatment options for conditions like keratoconus and irregular corneas in North America and worldwide. The transition of SynergEyes' manufacturing to CooperVision's facility in Gilbert, Arizona is expected to begin in 2023. SynergEyes' hybrid lens products complement CooperVision's existing Onefit scleral lenses. The collaboration is anticipated to provide eye care practitioners with diverse options and advanced technologies for better patient care.

BioSkryb Genomics has entered a multi-year partnership with Cooper Genomics to license its high-resolution single-cell genomic amplification technology. This collaboration aims to enhance preimplantation genetic testing (PGT) in reproductive health, addressing infertility that affects 15% of couples globally. The agreement permits Cooper Genomics to market BioSkryb's ResolveDNA^TM technology, which significantly improves testing accuracy and embryo viability assessment, potentially increasing live birth rates and reducing miscarriage and multiple pregnancies.